Patient-reported Outcomes of Topical Therapies in Actinic Keratosis: A Systematic Review

Overview

Journal Dermatol Ther

Specialty Dermatology

Date 2021 Feb 2

PMID 33527673

Citations 17

Authors

Ayman Grada

Steven R Feldman

Nicola Luigi Bragazzi

Giovanni Damiani

Affiliations

Soon will be listed here.

Abstract

Patients' perspectives on actinic keratosis treatments may have an impact on treatment adherence and, therefore, therapeutic outcomes. We performed a systematic review to assess patients' perspectives of topical, field-directed treatments for actinic keratoses. A literature search was conducted, and 14 studies were identified encompassing 4433 patients. Only four studies were focused on face and/or scalp, which are the locations that typically impact patients' quality of life. Four studies were clinical trials. One study utilized a validated patient-reported outcomes (PRO) instrument specifically developed for actinic keratosis. In general, treatment adherence and patient satisfaction were better with shorter-duration treatment regimens such as ingenol mebutate gel. Imiquimod improved quality of life in one study but not in another. No data was available on topical piroxicam. The findings underscore the need for effective and well-tolerated, short-duration topical treatment for actinic keratosis.

Citing Articles

Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment.

Valenti M, Bianco M, Narcisi A, Costanzo A, Borroni R, Ardigo M Dermatol Pract Concept. 2024; 14(3 S1).

PMID: 39133636 PMC: 11566729. DOI: 10.5826/dpc.1403S1a145S.

Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel.

Berman B, Armstrong A, Lebwohl M, Grada A, Bhatia N, Patel V JAAD Int. 2024; 16:192-198.

PMID: 39040844 PMC: 11262182. DOI: 10.1016/j.jdin.2023.09.006.

Advancements in elucidating the pathogenesis of actinic keratosis: present state and future prospects.

Wang Z, Wang X, Shi Y, Wu S, Ding Y, Yao G Front Med (Lausanne). 2024; 11:1330491.

PMID: 38566927 PMC: 10985158. DOI: 10.3389/fmed.2024.1330491.

Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis.

Singh R, McCain S, Feldman S JMIR Dermatol. 2023; 6:e39988.

PMID: 37632916 PMC: 10335144. DOI: 10.2196/39988.

Reasons for Patient Call-backs while being Treated with Topical 5-fluorouracil: A Retrospective Chart Review.

Singh R, Shah M, Feldman S J Clin Aesthet Dermatol. 2023; 16(6):53-54.

PMID: 37361358 PMC: 10286874.

References

Segatto M, Dornelles S, Silveira V, Frantz G . Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil. An Bras Dermatol. 2013; 88(5):732-8. PMC: 3798349. DOI: 10.1590/abd1806-4841.20132083. View

Salido-Vallejo R, Gonzalez-Velasco M, Guilabert M, Garcia E, Mira J . [The perception of care received by patients with actinic keratosis]. J Healthc Qual Res. 2018; 33(6):360-369. DOI: 10.1016/j.jhqr.2018.09.005. View

Grada A, Feldman S, Bragazzi N, Damiani G . Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review. Dermatol Ther. 2021; 34(2):e14833. PMC: 8047920. DOI: 10.1111/dth.14833. View

Agbai O, Davari P, Johnson J, Armstrong A, Fazel N . Effect of a Pre-Treatment Educational Video in Improving Patient Satisfaction with 5-Fluorouracil Treatment for Actinic Keratoses: A Randomized Controlled Trial. Dermatol Ther (Heidelb). 2016; 6(4):675-681. PMC: 5120637. DOI: 10.1007/s13555-016-0149-y. View

Yaldiz M . Prevalence of actinic keratosis in patients attending the dermatology outpatient clinic. Medicine (Baltimore). 2019; 98(28):e16465. PMC: 6641668. DOI: 10.1097/MD.0000000000016465. View

Augustin M, Tu J, Knudsen K, Erntoft S, Larsson T, William Hanke C . Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. J Am Acad Dermatol. 2015; 72(5):816-21. DOI: 10.1016/j.jaad.2015.01.036. View

Balcere A, Rone Kupfere M, cema I, Krumina A . Prevalence, Discontinuation Rate, and Risk Factors for Severe Local Site Reactions with Topical Field Treatment Options for Actinic Keratosis of the Face and Scalp. Medicina (Kaunas). 2019; 55(4). PMC: 6524034. DOI: 10.3390/medicina55040092. View

Emilio J, Schwartz M, Feldman E, Bieber A, Bienenfeld A, Jung M . Improved patient satisfaction using ingenol mebutate gel 0.015% for the treatment of facial actinic keratoses: a prospective pilot study. Clin Cosmet Investig Dermatol. 2016; 9:89-93. PMC: 4845892. DOI: 10.2147/CCID.S100999. View

Waalboer-Spuij R, Holterhues C, van Hattem S, Schuttelaar M, Gaastra M, Kuijpers D . Patient Perception of Imiquimod Treatment for Actinic Keratosis and Superficial Basal Cell Carcinoma in 202 Patients. Dermatology. 2015; 231(1):56-62. DOI: 10.1159/000381420. View

10.

Khanna R, Bakshi A, Amir Y, Goldenberg G . Patient satisfaction and reported outcomes on the management of actinic keratosis. Clin Cosmet Investig Dermatol. 2017; 10:179-184. PMC: 5439540. DOI: 10.2147/CCID.S121323. View

11.

Shergill B, Zokaie S, Carr A . Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence. 2014; 8:35-41. PMC: 3872140. DOI: 10.2147/PPA.S47126. View

12.

Dziunycz P, Schuller E, Hofbauer G . Prevalence of Actinic Keratosis in Patients Attending General Practitioners in Switzerland. Dermatology. 2018; 234(5-6):214-219. DOI: 10.1159/000491820. View

13.

Berman B, Tyring S, Nahm W, Osterdal M, Petersen A, Siegel D . Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial. J Clin Aesthet Dermatol. 2018; 10(11):26-32. PMC: 5774908. View

14.

Norrlid H, Norlin J, Holmstrup H, Malmberg I, Sartorius K, Thormann H . Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients. J Dermatolog Treat. 2017; 29(1):68-73. DOI: 10.1080/09546634.2017.1329514. View

15.

Stough D, Bucko A, Vamvakias G, Rafal E, Davis S . Fluorouracil cream 0.5% for the treatment of actinic keratoses on the face and anterior scalp: interim results of an 18-month open-label study. J Clin Aesthet Dermatol. 2010; 1(2):16-21. PMC: 2989824. View

16.

Esmann S, Vinding G, Christensen K, Jemec G . Assessing the influence of actinic keratosis on patients' quality of life: the AKQoL questionnaire. Br J Dermatol. 2012; 168(2):277-83. DOI: 10.1111/bjd.12036. View

17.

Longo I, Serra-Guillen C . Quality of Life, Behaviour and Attitudes towards Actinic Keratosis in Spain: The PIQA Study. Actas Dermosifiliogr (Engl Ed). 2018; 109(4):331-339. DOI: 10.1016/j.ad.2018.01.004. View

18.

Jubert-Esteve E, Del Pozo-Hernando L, Izquierdo-Herce N, Bauza-Alonso A, Martin-Santiago A, Jones-Caballero M . Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: a pilot study. Actas Dermosifiliogr. 2015; 106(8):644-50. DOI: 10.1016/j.ad.2015.04.014. View

19.

Cerio R . The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol. 2017; 31 Suppl 2:17-20. DOI: 10.1111/jdv.14091. View

20.

William Hanke C, Albrecht L, Skov T, Larsson T, Osterdal M, Spelman L . Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm on the chest: A phase 3 randomized controlled trial. J Am Acad Dermatol. 2019; 82(3):642-650. DOI: 10.1016/j.jaad.2019.07.083. View